[Edaily Starin Choi Hee-jae Reporter] Director Heo Jin-ho’s new film, *The Assassin(s)*, has surpassed 1 million cumulative viewers just four days after its release, establishing itself as a box office hit during the holiday season. (Photo courtesy of Hive Media Corp.) According to the Korean Film Council’s integrated computer network on the 26th, as of 7 a.m. that day, “The Assassin(s)” had recorded a cumulative audience of 1,047,760. This pace matches that of director Christopher Nolan’s new film “The Martian,” which has been enjoying a long-running box office success. Since its release on the 23rd, *The Assassin(s)* has topped the overall box office for three consecutive days and, on its fourth day in theaters, surpassed 1 million cumulative viewers, further fueling the box office fever during the Chuseok holiday. “The Assassin(s)” tells the story of the investigation into the suspicions and masterminds behind the First Lady assassination attempt on August 15, 1974, an event that shocked South Korea. Director Hur Jin-ho, known for films such as “Christmas in August,” “Spring, Summer, Fall, Winter… and Spring,” “Princess Deokhye,” and “Cheonmun: Asking the Sky,” helmed the project. The intense ensemble performances by the lead actors—Yoo Hae-jin, Park Hae-il, and Lee Min-ho—are driving high audience satisfaction. “The Assassin(s)” was named Runner-Up for the International Audience Award at the 51st Toronto International Film Festival. Following its official invitation to the Gala Presentation section, the film also made the list for an award decided by audience vote, confirming the positive local response to the film. (Photo courtesy of Hive Media Corp.)
“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
#The BORN Korea announced on the 13th that it posted a consolidated operating loss of 3.7 billion won in the third quarter of this year. This represents an improvement in the loss compared to the same…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…